For Immediate Release
Chicago, IL – August 30, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Alnylam Pharmaceuticals, Inc. (ALNY - Analyst Report), Monsanto Company (MON - Analyst Report), Novartis AG (NVS - Analyst Report), Biogen Idec Inc. , and Cubist Pharmaceuticals Inc. (CBST - Analyst Report).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Wednesday’s Analyst Blog:
Alnylam & Monsanto Collaborate
Alnylam Pharmaceuticals, Inc. (ALNY - Analyst Report) and Monsanto Company (MON - Analyst Report) recently formed a strategic alliance to implement biological technologies in the field of agriculture. As per the alliance, Alnylam’s broad RNAi-based (ribo nucleic acid interference) intellectual property (IP) and proprietary technologies along with Monsanto’s new BioDirect technology will help deliver innovative biological solutions to farmers.
As per the terms of the agreement, Monsanto, a leading global provider of technology-based solutions and agricultural products, will acquire worldwide, exclusive rights to use Alnylam’s technologies in the field of agriculture. Monsanto will be able to grant sub-licenses as well.
Alnylam will receive $29.2 million in upfront payments, along with milestone payments and other additional funding from Monsanto. The agreement also allows Alnylam to receive royalty payments on the products that will utilize the company’s platform technology and IP. With this alliance, Monsanto becomes Alnylam’s strategic partner in agriculture for the next 10 years.
We are pleased to see Alnylam stepping beyond its primary focus area. This will promote broader use of the company’s technology. Alnylam had earlier entered into key partnerships with companies like Novartis AG (NVS - Analyst Report), Biogen Idec Inc. , and Cubist Pharmaceuticals Inc. (CBST - Analyst Report) to share its RNAi know-how.
The Monsanto alliance will fetch upfront, milestone payments and other additional funding that will strengthen the company’s cash position. Alnylam exited the second quarter of 2012 with cash, cash equivalents and total marketable securities of around $293 million.
Besides these agreements, Alnylam makes use of its potentially revolutionary RNAi technology for the treatment of a wide array of diseases. The company expects to have five such RNAi therapeutic programs in advanced clinical development by the end of 2015. We expect investor focus to remain on the company’s pipeline going forward.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339